Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Development of New Low-Molecular-Weight Factor Xa Inhibitors that are Potential Anticoagulants

Author(s): Dmitry G. Tovbin, Dmitry N. Tarasov, Dmitry V. Malakhov, Natalia A. Tserkovnikova, Arseniy V. Aybush and Natalia N. Drozd*

Volume 19, Issue 1, 2022

Published on: 24 February, 2021

Article ID: e010921191770 Pages: 8

DOI: 10.2174/1568009621666210224104940

Abstract

Background: Despite the introduction of direct oral anticoagulants, the search for new oral anticoagulants remains an urgent task.

Objective: By using docking and scoring, based on physical methods, simple chemical rules, methods of synthesis, and activity measurement, develop new low-molecular-weight inhibitors of factor Xa, which are potential anticoagulants.

Methods: The development of leads was based on chemical synthesis and structure-based drug design methods. The basic idea was to combine the two approaches: one based on predictive modeling and the other based on the experimental data.

Results: In this study, we developed some nanomolar leads. Further chemical modification improved the inhibition constant by more than one order.

Discussion: The method proposed in this paper, as well as other methods, includes virtual screening, chemical synthesis, and activity measurement. However, the most time–consuming process in this method (chemical synthesis) was simplified, and the cost was reduced to the extent that was allowed; a very simple chemical reaction was chosen, i.e., the formation of an amide bond.

Conclusion: In this work, we demonstrated how using simple chemical rules based on the structurebased drug design, substances with a nanomolar concentration of activity can be developed.

Keywords: Chemical amide synthesis, antithrombotic drug, direct oral anticoagulant, drug design methods, Factor Xa (FXa), antithrombotic agents.

Graphical Abstract

[1]
Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR. Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem 2010; 53(17): 6243-74.
[http://dx.doi.org/10.1021/jm100146h] [PMID: 20503967]
[2]
De Candia M, Lopopolo G, Altomare C. Novel factor Xa inhibitors: a patent review Expert Opin Ther Patents 2009; 19: 1535-80.
[http://dx.doi.org/10.1517/13543770903270532]
[3]
Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67(1): 3-12.
[http://dx.doi.org/10.1023/A:1013985911759] [PMID: 11841335]
[4]
Leadley RJ Jr. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 2001; 1(2): 151-9.
[http://dx.doi.org/10.2174/1568026013395380] [PMID: 11899250]
[5]
Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30(43): 10363-70.
[http://dx.doi.org/10.1021/bi00107a001] [PMID: 1931959]
[6]
Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med 2012; 23(8): 692-5.
[http://dx.doi.org/10.1016/j.ejim.2012.10.001] [PMID: 23095463]
[7]
Toschi V, Lettino M. Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol 2011; 72(4): 563-80.
[http://dx.doi.org/10.1111/j.1365-2125.2011.04001.x] [PMID: 21545479]
[8]
Hirayama F, Koshio H, Ishihara T, et al. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan -1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. J Med Chem 2011; 54(23): 8051-65.
[http://dx.doi.org/10.1021/jm200868m] [PMID: 21995444]
[9]
Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarba- mimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 2009; 19(8): 2179-85.
[http://dx.doi.org/10.1016/j.bmcl.2009.02.111] [PMID: 19297154]
[10]
Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. Future Cardiol 2014; 10(1): 43-52.
[http://dx.doi.org/10.2217/fca.13.98] [PMID: 24344662]
[11]
Laskier V, Guy H, Fisher M, et al. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis. J Med Econ 2019; 22(10): 1063-72.
[http://dx.doi.org/10.1080/13696998.2019.1645679] [PMID: 31314619]
[12]
Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48(19): 5900-8.
[http://dx.doi.org/10.1021/jm050101d] [PMID: 16161994]
[13]
Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30(3): 376-81.
[http://dx.doi.org/10.1161/ATVBAHA.110.202978] [PMID: 20139357]
[14]
Le G, Yang C, Zhang M, et al. Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. Medicine (Baltimore) 2020; 99(49)e23055
[http://dx.doi.org/10.1097/MD.0000000000023055] [PMID: 33285683]
[15]
Li R, Yuan M, Cheng J, et al. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis. Thromb Res 2020; 196: 340-8.
[http://dx.doi.org/10.1016/j.thromres.2020.09.014] [PMID: 32977134]
[16]
Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50(22): 5339-56.
[http://dx.doi.org/10.1021/jm070245n] [PMID: 17914785]
[17]
Bhanwra S, Ahluwalia K. The new factor Xa inhibitor: Apixaban. J Pharmacol Pharmacother 2014; 5(1): 12-4.
[http://dx.doi.org/10.4103/0976-500X.124409] [PMID: 24554904]
[18]
Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2020; 13(3)e005969
[http://dx.doi.org/10.1161/CIRCOUTCOMES.119.005969] [PMID: 32148102]
[19]
Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol 2012; 60(4): 335-41.
[http://dx.doi.org/10.1097/FJC.0b013e31826265b6.] [PMID: 23064240]
[20]
Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: A systematic review and meta-analysis. Thromb Haemost 2020; 120(7): 1128-36.
[http://dx.doi.org/10.1055/s-0040-1712098] [PMID: 32365386]
[21]
Janczak DT, Mimier MK, McBane RD, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc 2018; 93(1): 40-7.
[http://dx.doi.org/10.1016/j.mayocp.2017.10.007] [PMID: 29217335]
[22]
Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018; 362: k2505.
[http://dx.doi.org/10.1136/bmj.k2505] [PMID: 29973392]
[23]
Chen L, Morrow JK, Tran HT, Phatak SS, Du-Cuny L, Zhang S. From laptop to benchtop to bedside: structure-based drug design on protein targets. Curr Pharm Des 2012; 18(9): 1217-39.
[http://dx.doi.org/10.2174/138161212799436386] [PMID: 22316152]
[24]
Langer T, Hoffmann R, Bryant S, Lesur B. Hit finding: towards ‘smarter’ approaches. Curr Opin Pharmacol 2009; 9(5): 589-93.
[http://dx.doi.org/10.1016/j.coph.2009.06.001] [PMID: 19576852]
[25]
Schulz MN, Hubbard RE. Recent progress in fragment-based lead discovery. Curr Opin Pharmacol 2009; 9(5): 615-21.
[http://dx.doi.org/10.1016/j.coph.2009.04.009] [PMID: 19477685]
[26]
Eitner K, Koch U. From fragment screening to potent binders: strategies for fragment-to-lead evolution. Mini Rev Med Chem 2009; 9(8): 956-61.
[http://dx.doi.org/10.2174/138955709788681645] [PMID: 19601891]
[27]
Orita M, Ohno K, Niimi T. Two ‘Golden Ratio’ indices in fragment-based drug discovery. Drug Discov Today 2009; 14(5-6): 321-8.
[http://dx.doi.org/10.1016/j.drudis.2008.10.006] [PMID: 19028598]
[28]
Tarasov D, Tovbin D. How sophisticated should a scoring function be to ensure successful docking, scoring and virtual screening? J Mol Model 2009; 15(3): 329-41.
[http://dx.doi.org/10.1007/s00894-008-0390-0] [PMID: 19066998]
[29]
Tarasov DN, Tovbin DG, Malakhov DV, et al. The development of new factor Xa inhibitors based on amide synthesis. Curr Drug Discov Technol 2018; 15(4): 335-50.
[http://dx.doi.org/10.2174/1570163815666180215114732] [PMID: 29468977]
[30]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[31]
Pauling L. The nature of the chemical bond. 3rd ed. Ithaca, NY: Cornell University Press 1960.
[32]
Sigma-Algrich 200. Available from:https://www.sigmaaldrich.com/technical-service-home/product-catalog.
[33]
Cammisotto V, Carnevale R, Nocella C, et al. Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin. Biochem Pharmacol 2019; 163: 111-8.
[http://dx.doi.org/10.1016/j.bcp.2019.02.016] [PMID: 30771281]
[34]
Wang W, Yuan J, Fu X, et al. Novel anthranilamide-based FXa inhibitors: Drug design, synthesis and biological evaluation. Molecules 2016; 21(4): 491.
[http://dx.doi.org/10.3390/molecules21040491] [PMID: 27089317]
[35]
Xing J, Yang L, Li H, et al. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation. Eur J Med Chem 2015; 95: 388-99.
[http://dx.doi.org/10.1016/j.ejmech.2015.03.052] [PMID: 25839438]
[36]
Xing J, Yang L, Yang Y, et al. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors. Eur J Med Chem 2017; 125: 411-22.
[http://dx.doi.org/10.1016/j.ejmech.2016.09.055] [PMID: 27689724]
[37]
Moreno-Fuquen R, Hurtado-Angulo M, Arango-Daraviña K, Bain G, Kennedy AR. Synthesis, crystal structure, Hirshfeld surface analysis, MEP study and mol-ecular docking of N-3-[(4-meth-oxy-phen-yl)carbamo-yl]phen-yl-3-nitro-benzamide as a promising inhibitor of hfXa. Acta Crystallogr E Crystallogr Commun 2020; 76(Pt 11): 1762-7.
[http://dx.doi.org/10.1107/S2056989020013730] [PMID: 33209349]

Rights & Permissions Print Cite
Article Metrics
37
1
© 2024 Bentham Science Publishers | Privacy Policy